Exane Derivatives’s Rhythm Pharmaceuticals RYTM Stock Holding History

Exane Derivatives’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$41	Sell	10 -10,223	-100%	-$56K	﹤0.01%	746
2022 Q1	$118K	Buy	10,233 +2,347	+30%	+$20.6K	0.03%	445
2021 Q4	$78.7K	Buy	+7,886	New	+$88.6K	0.02%	456
2021 Q3	–	Sell	-5,167	Closed	-$100K	–	1073
2021 Q2	$100K	Hold	5,167	–	–	0.02%	534
2021 Q1	$110K	Sell	5,167 -1,007	-16%	-$29.2K	0.03%	409
2020 Q4	$184K	Hold	6,174	–	–	0.05%	318
2020 Q3	$134K	Buy	6,174 +214	+4%	+$4.91K	0.04%	251
2020 Q2	$133K	Hold	5,960	–	–	0.04%	252
2020 Q1	$90.7K	Buy	+5,960	New	+$107K	0.03%	292

Other funds holding RYTM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Exane Derivatives's RYTM Position: Q2 2022 in Review

Exane Derivatives reduced its Rhythm Pharmaceuticals (RYTM) stake by 100% in Q2 2022, selling an estimated $56K and leaving 10 shares worth $41. The position accounts for ﹤0.01% of the portfolio, ranked #746.

Exane Derivatives first reported a position in RYTM in Q1 2020 and has held it in 9 quarters since. The position peaked at $184K in Q4 2020. 90 funds tracked by Wall St. Rank hold RYTM as of Q2 2022.

Exane Derivatives held 10 shares of Rhythm Pharmaceuticals worth $41 as of Q2 2022.
Exane Derivatives sold 10,223 Rhythm Pharmaceuticals shares in Q2 2022, an estimated $56K.
Rhythm Pharmaceuticals made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #746 holding.
Exane Derivatives first reported a position in Rhythm Pharmaceuticals in Q1 2020 and has held it in 9 quarters since.
Exane Derivatives's Rhythm Pharmaceuticals position peaked at $184K in Q4 2020.
90 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.